Lonc-term safety of TNF-blockers

被引：0
|
作者：
Van Vollenhoven, R. [1 ]
机构：
[1] Karolinska Inst, Stockholm, Sweden
来源：
CLINICAL AND EXPERIMENTAL RHEUMATOLOGY | 2008年 / 26卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：720 / 720
页数：1
相关论文
共 50 条
  • [21] Response to pneumococcal vaccination in patients with rheumatoid arthritis treated with TNF-blockers and/or methotrexate.
    Crnkic, M
    Saxne, T
    Sjöholm, A
    Truedsson, L
    ARTHRITIS AND RHEUMATISM, 2004, 50 (09): : S658 - S659
  • [22] Low incidence of first cardiovascular event in rheumatoid arthritis patients treated with TNF-blockers
    Jacobsson, LTH
    Turesson, C
    Gülfe, A
    Crnkic, M
    Petersson, IF
    Saxne, T
    Geborek, P
    ARTHRITIS AND RHEUMATISM, 2003, 48 (09): : S241 - S241
  • [23] TNF-blockers are not associated with an increased overall tumor risk in rheumatoid arthritis patients.
    Geborek, P
    Bladström, A
    Turesson, C
    Gülfe, A
    Crnkic, M
    Petersson, IF
    Saxne, T
    Olsson, H
    Jacobsson, LTH
    ARTHRITIS AND RHEUMATISM, 2003, 48 (12): : 3652 - 3653
  • [24] TocilizumabWas kommt nach TNF-Blockern im klinischen AlltagTocilizumabWhat comes after TNF-blockers in clinical routine
    P. Roll
    A. Rubbert-Roth
    H.-P. Tony
    Zeitschrift für Rheumatologie, 2010, 69 : 608 - 617
  • [25] HOW CAN TNF-BLOCKERS BE STOPPED WITHOUT FLARE? NEEDS EARLY TREATMENT AND IMMUNOLOGICAL REMISSION
    Saleem, Benazir
    Parmar, Rekha
    Goeb, Vincent
    Conaghan, Philip G.
    Ponchel, Frederique
    Emery, Paul
    RHEUMATOLOGY, 2009, 48 : I136 - I137
  • [26] How should we be defining a meaningful clinical response to TNF-blockers in ankylosing spondylitis patients?
    Stone, M.
    Cortinovis, D.
    Raj, A. Govinda
    Maetzel, A.
    Inman, R.
    Lapp, V.
    Beaton, D.
    ANNALS OF THE RHEUMATIC DISEASES, 2006, 65 : 544 - 544
  • [27] Drug Levels and Antibodies Against TNF-blockers in Spondyloarthritis and Rheumatoid Arthritis are Associated with the Activity but they do Not Predict it
    Marcela Padilla-Martinez, Erika
    Romero-Sanchez, Consuelo
    Manuel Bello-Gualtero, Juan
    Maria Mesa-Betancourt, Ana
    Bautista-Molano, Wilson
    Valle-O, Rafael
    CURRENT RHEUMATOLOGY REVIEWS, 2019, 15 (04) : 329 - 335
  • [28] Familial Mediterranean fever (FMF)-response to TNF-blockers used for treatment of FMF patients with concurrent inflammatory diseases
    Haj-Yahia, Soad
    Ben-Zvi, Ilan
    Lidar, Merav
    Livneh, Avi
    JOINT BONE SPINE, 2021, 88 (05)
  • [29] How many ankylosing spondylitis patients consulting private practice rheumatologists are candidates to TNF-blockers? The AS prisme survey
    Pham, T
    Flipo, R
    Saraux, A
    ANNALS OF THE RHEUMATIC DISEASES, 2005, 64 : 332 - +
  • [30] NO CLINICALLY RELEVANT CHANGES IN COAGULATION ACTIVATION BETWEEN PATIENTS INITIATING TNF-BLOCKERS VERSUS JAK-INHIBITORS
    Hansildaar, R.
    Raadsen, R.
    Heslinga, M.
    Nurmohamed, M. T.
    ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 1382 - 1382
12345